1.48

4.52% -0.07

Molecular Templates Inc (MTEM)

Overview News Price History Financials Discussions Forecast Stock Split

Molecular Templates Inc stock is currently priced at $1.48, with a 24-hour trading volume of 71,871. It has seen a -4.52% decreased in the last 24 hours and a -19.57% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.55 pivot point. If it approaches the $1.42 support level, significant changes may occur.

Previous Close:

$1.55

Open:

$1.61

24h Volume:

71,871

Market Cap:

$9.74M

Revenue:

$52.63M

Net Income/Loss:

$-8.12M

P/E Ratio:

-0.1189

EPS:

-12.45

Net Cash Flow:

$-42.02M

1W Performance:

-11.38%

1M Performance:

-19.57%

6M Performance:

-73.71%

1Y Performance:

+247.83%

1D Range:

$1.46

$1.62

52W Range:

$0.4125

$9.15

Molecular Templates Inc Stock (MTEM) Company Profile

Name

Molecular Templates Inc

Sector

Healthcare (1212)

Industry

Biotechnology (699)

Phone

512 869 1555

Address

9301 Amberglen Boulevard, Suite 100, Austin, TX

Employee

224

Twitter

@Moltemp

Next Earnings Date

2024-05-13

Latest SEC Filings

MTEM's Discussions on Twitter

Molecular Templates Inc Stock (MTEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-21	Initiated	BofA Securities	Buy
Feb-01-21	Initiated	UBS	Neutral
Sep-08-20	Initiated	Jefferies	Buy
Mar-25-20	Initiated	Stifel	Buy
Feb-27-20	Initiated	Barclays	Overweight
Apr-29-19	Initiated	UBS	Buy
Dec-11-18	Initiated	Oppenheimer	Outperform
Oct-08-18	Initiated	Laidlaw	Buy

View All

Molecular Templates Inc Stock (MTEM) Latest News

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

GlobeNewswire Inc.

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

GlobeNewswire Inc.

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

GlobeNewswire Inc.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March

Benzinga

Molecular Templates, Inc. Provides Interim Update

GlobeNewswire Inc.

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire Inc.

Molecular Templates Inc Stock (MTEM) Financials Data

Molecular Templates Inc (MTEM) Revenue 2024

MTEM reported a revenue (TTM) of $52.62 million for the quarter ending December 31, 2023, a +166.40% rise year-over-year.

Molecular Templates Inc (MTEM) Net Income 2024

MTEM net income (TTM) was -$8.12 million for the quarter ending December 31, 2023, a +91.24% increase year-over-year.

Molecular Templates Inc (MTEM) Cash Flow 2024

MTEM recorded a free cash flow (TTM) of -$42.02 million for the quarter ending December 31, 2023, a +54.44% increase year-over-year.

Molecular Templates Inc (MTEM) Earnings per Share 2024

MTEM earnings per share (TTM) was -$1.63 for the quarter ending December 31, 2023, a +93.36% growth year-over-year.

Molecular Templates Inc Stock (MTEM) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
BIOTECH TARGET N V	10% Owner	Jul 17 '23	Buy	0.47	4,255,319	2,000,000	15,447,322

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.